Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Brivekimig · 2 trials · 2 indications
Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) is defined as ≥75% reduction from Baseline in the total abscess and inflammatory nodule \[AN\] count, with no increase from Baseline in abscess or draining tunnel count.
Mixed meal tolerance test MMTT stimulated C-peptide concentration is to be calculated from area under the concentration-time curve (AUC)
| Arm | Type | Description |
|---|---|---|
| Brivekimig dose regimen A | EXPERIMENTAL | Participants will receive Brivekimig dose regimen A. |
| Brivekimig dose regimen B | EXPERIMENTAL | Participants will receive Brivekimig dose regimen B. |
| Brivekimig dose regimen C | EXPERIMENTAL | Participants will receive Brivekimig dose regimen C. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive Brivekimig matching placebo. |
| Brivekimig | EXPERIMENTAL | Participants will receive subcutaneous injection of brivekimig. |
| Name | Type | Description |
|---|---|---|
| Brivekimig | DRUG | * Pharmaceutical form: Solution for injection in vial * Route of administration: Subcutaneous injection |
| Placebo | DRUG | * Pharmaceutical form: Solution for injection in vial * Route of administration: Subcutaneous injection |
Inclusion Criteria: * Participants with a diagnosis of moderate to severe hidradenitis suppurativa (HS) for at least 6 months prior to Baseline * Participants must have HS lesions present in at least 2 distinct anatomic areas (eg, left and right axilla; or left axilla and left inguinocrural fold), ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Upadacitinib |
| Incyte Corporation | INCY | 6 | PHASE3 | Povorcitinib |
| Novartis AG Sponsored ADR | NVS | 11 | PHASE3 | Remibrutinib Dose A, Remibrutinib Dose B |
| MoonLake Immunotherapeutics Class A | MLTX | 2 | PHASE3 | Sonelokimab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | Brivekimig |
| Pfizer Inc. | PFE | 1 | PHASE2 | Ritlecitinib |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Zura Bio Limited Class A | ZURA | 1 | PHASE2 | Tibulizumab Dose A, Tibulizumab Dose B |
| Sonoma Pharmaceuticals, Inc. | SNOA | 2 | PHASE1 | SBT777101 |
| Evommune, Inc. | EVMN | 1 | EARLY_PHASE1 | EVO101 |
Brivekimig is an investigational small molecule being developed for hidradenitis suppurativa and type 1 diabetes mellitus. It is in Phase 2 clinical development for both conditions. Brivekimig is not approved by the FDA and remains under investigation.
Brivekimig is being developed by Sanofi, a biopharmaceutical company traded on the stock exchange under the ticker SNY. Sanofi is conducting Phase 2 clinical trials to evaluate the drug for hidradenitis suppurativa and type 1 diabetes mellitus.
Brivekimig is in Phase 2 clinical development. It is being studied in two separate Phase 2 trials, one for hidradenitis suppurativa and one for type 1 diabetes mellitus. The drug is investigational and has not received FDA approval.
Brivekimig is being evaluated in two Phase 2 clinical trials. NCT06812988 is studying the drug in type 1 diabetes mellitus with an enrollment of 84 participants. NCT07170917 is studying the drug in moderate to severe hidradenitis suppurativa with an enrollment of 208 participants.
Brivekimig is being studied in a Phase 2 trial for type 1 diabetes mellitus that describes the treatment as an anti-OX40L bispecific with anti-TNF activity in a single Nanobody molecule. This trial is registered under NCT06812988.